{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:39:10Z","timestamp":1792485550433,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ophtha.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:05:38Z","timestamp":1782749138000},"page":"1363-1369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8936-0132","authenticated-orcid":false,"given":"Jennifer","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0192-6951","authenticated-orcid":false,"given":"Michael X.","family":"Repka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-2418","authenticated-orcid":false,"given":"George A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-2369","authenticated-orcid":false,"given":"Daniel","family":"Vail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3823-4826","authenticated-orcid":false,"given":"Flora","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-3982","authenticated-orcid":false,"given":"Tedi","family":"Begaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-4224","authenticated-orcid":false,"given":"Ravi","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ophtha.2026.06.019_bib1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.ophtha.2020.06.012","article-title":"Intravitreal anti-vascular endothelial growth factor cost savings achievable with increased bevacizumab reimbursement and use","volume":"127","author":"Glasser","year":"2020","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.ophtha.2026.06.019_bib2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ophtha.2026.06.019_bib3","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ophtha.2026.06.019_bib4","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","article-title":"Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema","volume":"38","author":"Borchert","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2026.06.019_bib5","series-title":"Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds","year":"2025"},{"key":"10.1016\/j.ophtha.2026.06.019_bib7","article-title":"Harvard-Inovalon Medicare study: utilization and efficiency under Medicare Advantage vs. Medicare Fee-for-Service","author":"Vabson","year":"2023","journal-title":"Inovalon"},{"key":"10.1016\/j.ophtha.2026.06.019_bib8","author":"Freed"},{"key":"10.1016\/j.ophtha.2026.06.019_bib9","article-title":"Medicare will require prior approval for certain procedures","author":"Abelson","year":"2025","journal-title":"The New York Times"},{"issue":"15","key":"10.1016\/j.ophtha.2026.06.019_bib10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.2022.17732","article-title":"Improving prior authorization in Medicare Advantage","volume":"328","author":"Anderson","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ophtha.2026.06.019_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.37765\/ajmc.2023.89426","article-title":"Varied use of step therapy among Medicare Advantage plans","volume":"29","author":"Jenkins","year":"2023","journal-title":"Am J Manag Care"},{"issue":"3","key":"10.1016\/j.ophtha.2026.06.019_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","article-title":"Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and Medicare Advantage patients","volume":"124","author":"Parikh","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2026.06.019_bib13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.oret.2021.03.003","article-title":"Use of bevacizumab injections in Medicare Fee For Service in the IRIS\u00ae Registry","volume":"5","author":"Repka","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ophtha.2026.06.019_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.4868","article-title":"High-cost cancer drug use in Medicare Advantage and traditional Medicare","volume":"6","author":"Bradley","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"8","key":"10.1016\/j.ophtha.2026.06.019_bib15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","article-title":"Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis","volume":"104","author":"Li","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2026.06.019_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ophtha.2025.01.022","article-title":"Twenty-year trends in prevalence and incidence of diabetic retinal disease","volume":"132","author":"VanderBeek","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.06.019_bib17","author":"Biniek"},{"key":"10.1016\/j.ophtha.2026.06.019_bib18","author":"Ochieng"},{"issue":"2","key":"10.1016\/j.ophtha.2026.06.019_bib19","first-page":"147","article-title":"Comparison of ophthalmic medication prices between the United States and Australia","volume":"136","author":"Parikh","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2026.06.019_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ophtha.2023.04.019","article-title":"The biosimilar paradox: how anti-vascular endothelial growth factor biosimilars could increase patient and overall health care costs","volume":"130","author":"Zhang","year":"2023","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2026.06.019_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0335390","article-title":"US trends of anti-vascular endothelial growth factor use from 2017-223: an analysis of medicare, mediciad, and commercial insurance","volume":"21","author":"Malhotra","year":"2026","journal-title":"PloS One"},{"key":"10.1016\/j.ophtha.2026.06.019_bib22","author":"Freed"},{"issue":"8","key":"10.1016\/j.ophtha.2026.06.019_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.oret.2025.03.014","article-title":"Anti-VEGF use for conditions without US Food and Drug Administration approval","volume":"9","author":"Parikh","year":"2025","journal-title":"Ophthalmol Retina"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026004537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026004537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:56:21Z","timestamp":1792482981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026004537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0161642026004537"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.06.019","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}